Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer

摘要: Purpose This preclinical and phase II study evaluated the efficacy safety of combination cetuximab erlotinib in metastatic colorectal cancer (mCRC). Patients Methods The activity mechanism action plus were investigated vitro cell lines. In clinical study, patients with chemotherapy-refractory mCRC treated 400 mg/m2 as a loading dose then weekly 250 100 mg orally daily. primary end point was response rate (RR), which separately KRAS wild-type (WT) versus mutant tumors. Secondary points included toxicity, progression-free survival (PFS), overall survival. Target accrual 50 patients, one-stage design. Results Preclinical studies demonstrated synergistic cotreatment on growth inhibition colon lines both result enhanced epidermal facto...